［1］Geffner M1,Lundberg M,KoltowskaHaggstrёm M,et al.Changes in height,weight,and body mass index in children with craniopharyngioma after three years of growth hormone therapy:analysis of KIGS (Pfizer International Growth Database)［J］.J Clin Endocrinol Metab,2004,89(11):5435-5440.
［2］潘祥林，王鸿利.诊断学的任务与发展方向［J/CD］.中华诊断学电子杂志，2013，1（1）：8-9.
［3］Li GM，SunXJ，Shao P．Postoperative pituitary hormonal disturbances and hormone replacement therapy time and dosage in children with craniopharyngiomas［J］．Chin Med J(Engl)，2008，121(20)：2077-2082．
［4］Karavitaki N，Brufani C，Warner JT，et al．Craniopharyngiomas in children and adults：systematic analysis of 121 cases with longterm follow-up［J］.Clin Endocrinol(Oxf),2005,62(4):397-409.
［5］Ghigo E,Aimaretti G,Corneli G.Dignosis of adult GH deficiency［J］．Growth Horm IGF Res,2008,18(1):1-16.
［6］Darendeliler F,Karagiannis G,Wilton P,et al.Recurrence of brain tumours in patients treated with growth hormone:analysis of KIGS (Pfizer International Growth Database)［J］.Acta pediatrica,2006,95(10):1284-1290.
［7］Karavitaki N,Warner JT,Marland A,et al.GH replacement does not increase the risk of recurrence in patients with craniopharyngioma［J］.Clin Endocrinol，2006，64(4)：556-560.
［8］Olsson DS,Buchfelder M,Wiendieck K,et al.Tumour recurrence and enlargement in patients with craniopharyngioma with and without GH replacement therapy during more than 10 years of follow-up［J］.Eur J Endocrinol,2012,166(6):1061-1068.
